Intestinal Neoplasms  >>  Caprelsa (vandetanib)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Caprelsa (vandetanib) / Sanofi
NCT00499850: Phase I FOLFOX Combination

Completed
1
18
RoW
ZD6474 (vandetanib), ZACTIMA™, 5-Fluorouracil, 5-FU, Leucovorin, Oxaliplatin
Genzyme, a Sanofi Company
Advanced Colorectal Carcinoma
06/06
04/08
NCT00496509: Phase I Efficacy On Vascular Permeability In Patients With Advanced Colorectal Cancer

Completed
1
24
Europe
ZD6474 (Zactima) 100mg, Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MR), Biomarker Draws, ZD6474 (Zactima) 300mg
Genzyme, a Sanofi Company
Colorectal Cancer
10/07
10/07
NCT00532909: Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer

Completed
1
13
US
Vandetanib, Capecitabine, Oxaliplatin, Bevacizumab
Branimir Sikic, AstraZeneca
Anal, Colon, and Rectal Cancers, Colorectal Neoplasms, Colon/Rectal Cancer
05/10
05/10
NCT00436072: ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer

Checkmark P1 data (CRC)
Jun 2012 - Jun 2012: P1 data (CRC)
Completed
1
46
US
ZD6474, Cetuximab, Irinotecan
Dana-Farber Cancer Institute, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, AstraZeneca
Colorectal Cancer
02/12
08/12

Download Options